gpr4

GPR4 antagonist 1 is a GPR4 antagonist with an IC50 of 189 nM.

NE 52-QQ57 is a selective, orally available antagonist of GPR4 (IC50: 70 nM) with anti-inflammatory activity.

GPR40 Agonist 2 is a compound that functions as a GPR40 agonist and is utilized in diabetes research.

GPR40 Activator 1 is a potent activator of GPR40 for the treatment of type 2 diabetes.

GPR40 Activator 2 is a highly effective activator of the GPR40 receptor.

GPR40/FFAR1 modulator 1 is a Gq-coupled free fatty acid receptor 1 (GPR40/FFAR1) agonist and allosteric modulator.

GPR40 agonist 1 is an effective new GPR40 agonist (EC50s: 17 nM and 2 nM for rGPR40 and hGPR40).

GPR40 Activator 3 (compound SC) is a potent activator of GPR40. It alleviates pulmonary fibrosis by inhibiting M2 macrophage polarization through the GPR40/PKD1/CD36 axis.

GPR41 modulator 2 (Compound 10bx) acts as an agonist of the G protein-coupled receptor (GPR41).

GPR41 modulator 1 (compound 10ak) is a potent modulator of GPR41 with an EC50 value of 0.679 µM, demonstrating agonistic modulating activity.

GPR40 agonist 6 (Compound 7a) is a potent and selective agonist of free fatty acid receptor 1 (FFAR1 or GPR40) with an EC50 of 0.058 μM against GPR40 [1].

GPR41 agonist-1 is a GPR41 agonist, useful for studying metabolic diseases such as diabetes and obesity.

GPR40 agonist 5 is an orally active GPR40 (G protein-coupled receptor 40) agonist (EC50: 47 nM). gPR40 agonist 5 reduces blood glucose levels and improves glucose tolerance. gPR40 agonist 5 shows adequate control of hyperglycemic state in type 2 diabetic mice.

Compound 1, also known as GPR40 agonist 7, is an orally active agonist of the G protein-coupled receptor 40 (GPR40). It effectively enhances the secretion of insulin and GLP-1, exhibiting a hypoglycemic effect in vivo with an ED 50 of 0.58 mg/kg [1].

Anti-GPR44/PTGDR2/CD294 Antibody is a CHO-expressed human antibody targeting GPR44/PTGDR2/CD294. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Chikusetsusaponin IVa (Calenduloside F) is a novel AMPK activator, can induce insulin secretion from βTC3 cells via GPR4 mediated calcium and PKC pathways, may be developed into a new potential for therapeutic agent used in T2DM patients.

AMG 837 sodium salt is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents. IC50 value: 13 nM (EC50) [1] Target: GPR40 agonist AMG 837 displayed the expected t